Androgen deprivation therapy (ADT) given to men with prostate cancer causes rapid and severe sex steroid deficiency, leading to increased bone remodeling and accelerated bone loss. To examine the effects of a single dose of zoledronic acid on bone microarchitecture, we conducted a 2-year randomized placebo controlled trial in 76 men, mean age (interquartile range [IQR]) 67.8 years (63.8 to 73.9) with non-metastatic prostate cancer commencing adjuvant ADT; 39 were randomized to zoledronic acid and 37 to matching placebo. Bone microarchitecture was measured using high-resolution peripheral quantitative computed tomography (HR-pQCT). Using a mixed model, mean adjusted differences (MAD; 95% confidence interval [95% CI]) between the groups are r...
Objective To evaluate the effect of annual infusions of zoledronic acid (ZA) with or without a sing...
<p>There was no significant change in bone surface area (A) induced by the presence of a tumour or t...
Summary: Changes in bone mineral density and bone strength following treatment with zoledronic acid ...
BACKGROUND: Fractures in men are a major health issue, and data on the antifracture efficacy of ther...
Background : Fractures in men are a major health issue, and data on the antifracture efficacy of the...
Background: Animal studies suggest that undercarboxylated osteocalcin may improve insulin sensitivit...
Objective To study the influence of adjuvant androgen suppression and bisphosphonates on incident ve...
Androgen deprivation therapy (ADT) is known to cause bone loss in a majority of patients with castra...
The results of the well-conducted trial by Saad et al. (1) have prompted many to consider routine us...
BACKGROUND: We studied 265 men (mean age 56.4 years; range 18-83 years), among patients enrolled in ...
BACKGROUND: We studied 265 men (mean age 56.4years; range 18-83years), among patients enrolled in tw...
Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) wer...
Summary\ud Changes in bone mineral density and bone strength following treatment with zoledronic aci...
Zoledronic acid is a bisphosphonate that is effective in the treatment of complications of metastati...
AbstractPurposeThe ZOTECT study assesses the effect of zoledronic acid (ZOL) on bone-marker levels a...
Objective To evaluate the effect of annual infusions of zoledronic acid (ZA) with or without a sing...
<p>There was no significant change in bone surface area (A) induced by the presence of a tumour or t...
Summary: Changes in bone mineral density and bone strength following treatment with zoledronic acid ...
BACKGROUND: Fractures in men are a major health issue, and data on the antifracture efficacy of ther...
Background : Fractures in men are a major health issue, and data on the antifracture efficacy of the...
Background: Animal studies suggest that undercarboxylated osteocalcin may improve insulin sensitivit...
Objective To study the influence of adjuvant androgen suppression and bisphosphonates on incident ve...
Androgen deprivation therapy (ADT) is known to cause bone loss in a majority of patients with castra...
The results of the well-conducted trial by Saad et al. (1) have prompted many to consider routine us...
BACKGROUND: We studied 265 men (mean age 56.4 years; range 18-83 years), among patients enrolled in ...
BACKGROUND: We studied 265 men (mean age 56.4years; range 18-83years), among patients enrolled in tw...
Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) wer...
Summary\ud Changes in bone mineral density and bone strength following treatment with zoledronic aci...
Zoledronic acid is a bisphosphonate that is effective in the treatment of complications of metastati...
AbstractPurposeThe ZOTECT study assesses the effect of zoledronic acid (ZOL) on bone-marker levels a...
Objective To evaluate the effect of annual infusions of zoledronic acid (ZA) with or without a sing...
<p>There was no significant change in bone surface area (A) induced by the presence of a tumour or t...
Summary: Changes in bone mineral density and bone strength following treatment with zoledronic acid ...